

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Reviewer—ACP	Health Care—Staff Physician						
Luis C. Afonso	Content Reviewer—ACC Task Force on Expert Consensus Decision Pathways	Professor, Wayne State University School of Medicine—Professor; Harper University Hospital, Detroit Medical Center—Program Director, Adult Cardiovascular Fellowship, Director Echocardiography Laboratory	<ul style="list-style-type: none"> • Zoll Medical† 	None	None	None	None	None
Roger S. Blumenthal	Content Reviewer—ACC Dyslipidemia Clinical Topic Collection	Johns Hopkins Hospital Ciccarone Preventive Cardiology Center—Pollin Professor of Cardiology	None	None	None	None	None	None
Deborah S. Croy	Content Reviewer—Cardiovascular Team Section Leadership Council	Bland County Medical Clinic—Adult Cardiovascular Nurse Practitioner	None	None	None	None	None	None
Stephen R. Daniels	Content Reviewer—ACPC Section Leadership Council	University of Colorado School of Medicine—Professor and Chair, and Jeanette Leeser, Grants Program Director, Department of Pediatrics; The Children’s Hospital Colorado—Pediatrician-in-Chief	<ul style="list-style-type: none"> • Sanofi-Aventis 	None	None	<ul style="list-style-type: none"> • Novo Nordisk (DSMB) 	None	None
Joseph E. Marine	Content Reviewer—ACC Task Force on Expert Consensus Decision Pathways	Johns Hopkins University School of Medicine—Associate Professor of Medicine	None	None	None	None	<ul style="list-style-type: none"> • UpToDate 	None
Jennifer G. Robinson	Content Reviewer—2013 ACC Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults	University of Iowa—Professor, Departments of Epidemiology and Medicine; Director, Prevention Intervention Center	<ul style="list-style-type: none"> • Akcea/Ionis • Amgen* • Eli Lilly* • Esperion • Merck • Pfizer • Sanofi-Regeneron* 	None	None	<ul style="list-style-type: none"> • Amarin* • Amgen* • AstraZeneca* • Eli Lilly* • Esai* • Esperion* • GlaxoSmithKline* • Merck* 	None	None

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
						<ul style="list-style-type: none"> • Pfizer* • Regeneron* • Sanofi-Aventis* • Takeda* 		
Laura J. Ross	Content Reviewer—ACC Cardiovascular Team Section Leadership Council	Park Nicollet—Physician Assistant	None	None	None	None	None	None
Joseph J. Saseen	Content Reviewer—Cardiovascular Team Section Leadership Council	University of Colorado Anschutz Medical Campus—Professor and Vice Chair, Department of Clinical Pharmacy, Professor, Department of Family Medicine	None	None	None	None	• NLA†	• Defendant, myopathy from statin dosage, 2016
Michael D. Shapiro	Content Reviewer—Prevention Section Leadership Council	Oregon Health & Science University—Associate Professor of Medicine and Radiology; Knight Cardiovascular Institute—Director, Cardiac MR CT Program Center for Preventive Cardiology	<ul style="list-style-type: none"> • Akcea • Alexion • Amgen • Bracco • GE Healthcare* 	None	None	<ul style="list-style-type: none"> • Akcea† • Amarin† • Amgen† 	None	None
Barbara S. Wiggins	Content Reviewer—ACC Task Force on Expert Consensus Decision Pathways	Medical University of South Carolina—Clinical Pharmacy Specialist Cardiology, Department of Pharmacy Services	None	None	None	None	None	None

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statins Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Brendan M. Everett	Official Reviewer—ACC Task Force on Clinical Expert	Brigham and Women's Hospital—Director, General Cardiology Inpatient Service;	<ul style="list-style-type: none"> ▪ Roche 	None	None	<ul style="list-style-type: none"> ▪ Novartis* ▪ Roche* 	None	None

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Council							
Sarah A. Spinler	Organizational Reviewer—ACCP	Philadelphia College of Pharmacy, University of the Sciences in Philadelphia—Professor of Clinical Pharmacy	<ul style="list-style-type: none"> ▪ AstraZeneca ▪ Daiichi-Sankyo 	None	None	None	None	None
Karol E. Watson	Organizational Reviewer—ABC	UCLA Medical School—Co-Director, UCLA Program in Preventive Cardiology	<ul style="list-style-type: none"> ▪ AstraZeneca ▪ Daiichi-Sankyo ▪ GlaxoSmithKline 	None	None	<ul style="list-style-type: none"> ▪ Merck (DSMB) 	None	None
Amy R. Woods	Organizational Reviewer—ACP	Northeast Mississippi Health Care—Staff Physician	None	None	None	None	None	None
Luis C. Afonso	Content Reviewer—ACC Task Force on Clinical Expert Consensus Documents	Wayne State University School of Medicine—Professor; Harper University Hospital, Detroit Medical Center—Program Director, Adult Cardiovascular Fellowship; Director, Echocardiography Laboratory	None	None	None	None	None	None
Deborah S. Croy	Content Reviewer—Cardiovascular Team Council	Bland County Medical Clinic—Adult Cardiovascular Nurse Practitioner	None	None	None	None	None	None
Stephen R. Daniels	Content Reviewer—Adult Congenital and Pediatric Cardiology Council	University of Colorado School of Medicine—Chair, Department of Pediatrics; The Children’s Hospital Colorado—Pediatrician-in-Chief; L. Joseph Butterfield Chair in Pediatrics	<ul style="list-style-type: none"> ▪ Sanofi-Aventis 	None	None	None	None	None
Scott M. Grundy	Content Reviewer—Chair, Update to ACC/AHA Cholesterol Guideline	University of Texas Southwestern Medical Center at Dallas—Professor of Internal Medicine	None	None	None	None	None	None
James L. Januzzi	Content Reviewer—Chair, ACC Task Force on Clinical Expert Consensus Documents	Massachusetts General Hospital—Director, Dennis and Marilyn Barry Fellowship in Cardiology	<ul style="list-style-type: none"> ▪ Novartis* ▪ Roche* 	None	None	<ul style="list-style-type: none"> ▪ Amgen (DSMB) 	None	None

Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		Research Cardiology Division; Harvard Medical School—Hutter Family Professor of Medicine						
Joseph J. Saseen	Content Reviewer— Cardiovascular Team Council	University of Colorado Anschutz Medical Campus—Professor and Vice Chair, Department of Clinical Pharmacy, Professor, Department of Family Medicine	None	None	None	None	None	None
Michael D. Shapiro	Content Reviewer— Prevention Council	Oregon Health & Science University—Associate Professor of Medicine and Radiology; Knight Cardiovascular Institute—Director, Cardiac MR CT Program Center for Preventive Cardiology	None	None	None	<ul style="list-style-type: none"> ▪ Amarin† ▪ Amgen† ▪ Isis† ▪ Sanofi† ▪ Synageva† 	None	None
Barbara S. Wiggins	Content Reviewer— ACC Task Force on Clinical Expert Consensus Documents	Medical University of South Carolina—Clinical Pharmacy Specialist Cardiology, Department of Pharmacy Services	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* Significant relationship.

† No financial benefit.

ABC indicates Association of Black Cardiologists; ACC=American College of Cardiology; ACP=American College of Physicians; ACCP=American College of Clinical Pharmacy; AHA, American Heart Association; CT, computed tomography; DSMB, Data Safety Monitoring Board; MR, magnetic resonance; NIH=National Institutes of Health; NHLBI=National Heart, Lung, and Blood Institute; NLA=National Lipid Association; PCNA= Preventive Cardiovascular Nurses Association.